Top 20 Diagnostics Companies of 2025 

Top 20 Diagnostics Companies of 2025 

Shots: 

• Driven by continuous innovation and enhanced precision, the diagnostic industry is advancing rapidly, transforming the way healthcare is delivered 

• In 2025, the global diagnostic testing market is valued at approximately $207.96B in 2025 and is projected to grow to around $272.9B by 2034, reflecting a CAGR of 3%. Siemens Healthineers reclaims its first position with a revenue of $17.61B, followed by GE Healthcare and Roche with $16.49B and $15.85B, respectively  

• PharmaShots brings a concise report on the Top 20 Diagnostic Companies of 2025.  

Note:  These companies are ranked based on their diagnostics (including imaging) segment revenue.  

20. Eurofins Scientific 

Diagnostic Segment Revenue: $1.42B 

Founded Year: 1987 

Total Employees: 62700 

Headquarters: Luxembourg 

Market Cap:  

Stock Exchange: EPA 

• Eurofins Scientific is a French group of laboratories that provides testing and support services to industries and governments across the pharmaceutical, food, environmental, agriscience, and consumer products sectors 

• Eurofins operates in four business segments: Life Science, BioPharma, Diagnostic Services & Products, and Consumer & Technology Products Testing. In 2024, the company recorded a 1.42% increase in revenue compared to 2023, driven by higher sales in the Diagnostic Services & Products segment 

• In October 2024, Eurofins agreed to acquire SYNLAB’s clinical diagnostics operations in Spain and completed the acquisition in April 2025 

19. Lantheus Holdings 

Diagnostic Segment Revenue: $1.49B 

Founded Year: 1956 

Total Employees: 808 

Headquarters:  Massachusetts, United States 

Market Cap:  

Stock Exchange: NASDAQ 

• Lantheus is a global radiopharmaceutical company specializing in the development, manufacturing, and commercialization of radiotherapies and precision diagnostic products 

• The company focuses on three segments Radiopharmaceutical Oncology and Precision Diagnostics. In 2024, the company revenue increased by 15.50% as compared to 2023, driven by higher sales in precision diagnostic segment  

• In July 2024, Lantheus acquired Meilleur Technologies and added NAV-4694, a ß Amyloid PET Imaging Agent for Alzheimer’s Disease to its product portfolio 

18. Revvity 

Diagnostic Segment Revenue: $1.5B 

Founded Year: 1947 

Total Employees: 11,000 

Headquarters:  Massachusetts, United States 

Market Cap:  

Stock Exchange: NYSE 

• Revvity is an American company, formerly known as PerkinElmer, that focuses on the development of cell and gene therapy solutions 

• Revvity operates through two main business segments: Life Sciences and Diagnostics. The company offers a range of products, including EnVision and VICTOR Nivo. In 2024, Revvity reported a 3.44% increase in revenue compared to 2023, driven by higher sales in immunodiagnostics and reproductive health 

• In November 2024, Scale Biosciences and Revvity’s BioLegend launched the TotalSeq Phenocyte single-cell protein profiling solution, enabling high-parameter protein profiling of single-cells 

17. Bio-Rad Laboratories 

Diagnostic Segment Revenue: $1.54B 

Founded Year:1952  

Total Employees: 7700 

Headquarters:  Hercules, California 

Market Cap:  

Stock Exchange: NYSE 

• Bio-Rad Laboratories is an American company that develops, manufactures, and markets products for the life science research and clinical diagnostics markets 

• The company operates through two main business segments: Life Science and Clinical Diagnostics, offering test systems, informatics systems, test kits, and specialized quality controls. Droplet Digital is one of Bio-Rad’s flagship products. In 2024, the company reported a 4.05% increase in revenue compared to 2023, primarily driven by higher demand for quality control and blood typing products 

• In July 2024, Bio-Rad launched the ChemiDoc Go Imaging System, a solution for gel and Western blot imaging 

16. Hologic 

Diagnostic Segment Revenue: $1.68B 

Founded Year: 1958 

Total Employees:7063  

Headquarters:  Massachusetts, United States 

Market Cap:  

Stock Exchange: NASDAQ 

• Hologic Inc. is a U.S.-based company focused on advancing women’s health. It develops and manufactures diagnostic products, medical imaging systems, and surgical solutions 

• The company operates through three main business segments: Diagnostics, Breast and Skeletal Health (Medical Imaging), and GYN Surgical Products. Its portfolio includes products such as Acessa Laparoscopic Radiofrequency Ablation (Lap-RFA) and Aptima Sexual and Vaginal Health Solutions. In 2024, Hologic revenue rose 1.81% year-over-year due to increased sales 

• In January 2024, Hologic completed the acquisition of Gynesonics for approximately $350M, further expanding its surgical offerings 

15. Natera 

Diagnostic Segment Revenue: $1.69B 

Founded Year: 2004 

Total Employees: 4434 

Headquarters: Texas,United States 

Market Cap:  

Stock Exchange: NASDAQ 

• Natera is a clinical genetic testing company headquartered in Austin, Texas, specializing in non-invasive, cell-free DNA technology. The company focuses on women’s health, oncology, and organ health 

• Natera’s notable products include Panorama and Horizon. In 2024, the company saw a 56.48% year-over-year revenue increase, driven by higher sales of its women’s health products 

• In November 2024, Natera’s Prospera Lung test received CMS MolDX coverage for single-lung transplant surveillance, further expanding its offerings in organ health 

14. QuidelOrtho 

Diagnostic Segment Revenue: $2.78B 

Founded Year: 1979 

Total Employees: 6600 

Headquarters:  California, United States 

Market Cap:  

Stock Exchange: NASDAQ 

• QuidelOrtho is a U.S.-based global diagnostics company specializing in the development, manufacturing, and distribution of in-vitro diagnostic products 

• The company operates across four key segments: Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Notable products include the ELVIS HSV Test System and FreshCells Cell Culture. In 2024, QuidelOrtho’s total revenue declined by 7.02% year-over-year, primarily due to decreased sales in the Point-of-Care and Molecular Diagnostics segments 

• In April 2024, the company received FDA 510(k) clearance for its QuickVue COVID-19 Test 

13. Bruker 

Diagnostic Segment Revenue: $3.09B 

Founded Year: 1960 

Total Employees: 11396 

Headquarters:  Massachusetts, United States 

Market Cap:  

Stock Exchange: NASDAQ 

• Bruker Corporation designs, manufactures and distributes scientific instruments for molecular and materials research, as well as diagnostic solutions 

• Bruker operates through four main segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST). Its product lineup includes CBRNE detectors, elemental analyzers, and other advanced analytical tools. In 2024, Bruker’s revenue grew by 14.44% year-over-year, driven by strong performance across the BSI BioSpin, BSI CALID, BSI Nano, and BEST segments 

• In June 2024, Bruker launched the neofleX MALDI-TOF system, designed for spatial biology and mass spectrometry imaging applications  

12. Sysmex 

Diagnostic Segment Revenue: $3.15B 

Founded Year: 1968 

Total Employees: 11457 

Headquarters:  Kobe, Japan 

Market Cap:  

Stock Exchange: TYO 

• Sysmex Corporation is a Japanese multinational company specializing in clinical diagnostics and laboratory solutions, with global recognition in the field of hematology 

• The company focuses primarily on in-vitro diagnostics, particularly hematology. In the U.S., notable products include the XN-9100, RU-20, and BT-50 systems. In 2024, Sysmex reported a 2.27% year-over-year revenue increase, driven by strong hematology sales 

• In April 2024, Sysmex began direct sales and service operations in Italy for its hematology, urinalysis, and hemostasis product lines, enhancing its market presence in Europe 

11. Canon 

Diagnostic Segment Revenue: $3.61B 

Founded Year: 1937 

Total Employees: 13289 

Headquarters: Tokyo,Japan 

Market Cap:  

Stock Exchange: TYO 

• Canon Inc. is a Japan-based global company known for manufacturing multifunctional devices, with a strong focus on optical, imaging, and industrial technologies 

• The company operates through four main business segments: Printing, Medical, Imaging, and Industrial. In the Medical segment, notable products include the Vantage Galan 3T MRI system and the INSTINX platform. In 2024, Canon’s revenue declined by 7.9% year-over-year, impacted by softness across key markets 

• In November 2024, Canon initiated a research collaboration with Penn Medicine to explore applications of Photon-Counting CT technology 

10. IDEXX Laboratories 

Diagnostic Segment Revenue: $3.71B 

Founded Year: 1983 

Total Employees: 11000 

Headquarters:  Westbrook, United States 

Market Cap:  

Stock Exchange: NASDAQ 
 

• IDEXX Laboratories is a global American company specializing in diagnostics for companion animals, livestock, and water testing 

• IDEXX operates across three segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy. Key products include the Catalyst One Chemistry Analyzer and ImageVue DR30 Digital Imaging System. In 2024, IDEXX reported a 6.3% revenue increase over 2023, driven largely by growth in CAG Diagnostics’ recurring revenue 

• In January 2024, the company launched the Vue Dx Cellular Analyzer, enhancing in-clinic detection of cytologic changes in ear and blood samples 

9. Thermo Fisher Scientific 

Diagnostic Segment Revenue: $4.51B 

Founded Year: 1956 

Total Employees: 125000 

Headquarters:  Massachusetts, United States 

Market Cap:  

Stock Exchange: NYSE 

• Thermo Fisher Scientific is an American provider of analytical equipment, life sciences solutions, specialized diagnostics, laboratory, pharmaceutical, and biotechnology services   

• Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products, and Biopharma Services are four areas in which the company operates. Specialty Diagnostics has five primary businesses – Clinical Diagnostics, Immuno Diagnostics, Microbiology, Transplant Diagnostics, and our Healthcare Market Channel. In 2024, the company’s revenue increased by 2.5% as compared to 2023, majorly driven by growth in the immunodiagnostics and transplant diagnostics businesses 

• In August 2024, Thermo Fisher HLA Typing Kit 510(k) Clearance for use as companion diagnostic with a T-Cell receptor therapy for synovial sarcoma 

8. Becton-Dickinson and Company 

Diagnostic Segment Revenue: $5.2 B 

Founded Year: 1897 

Total Employees: 74000 

Headquarters:  New Jersey, US 

Market Cap:  

Stock Exchange: NYSE 

• Becton, Dickinson and Company (BD) is a global medical technology firm that specializes in the development, manufacturing, and commercialization of medical devices, diagnostic systems, and laboratory reagents. In select regions, BD also provides consulting and data analytics services to support healthcare operations and improve clinical outcomes 

• BD’s flagship products—BD Veritor, PureWick, and BD Pyxis—are widely recognized and trusted across the healthcare industry. In 2024, the company reported a 1.76% year-over-year revenue increase, driven primarily by strong performance in its Life Sciences segment 

• In July 2024, BD announced a global collaboration agreement with Quest Diagnostics to co-develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx). This strategic partnership aims to advance precision medicine for the treatment of cancer and other complex diseases 

7. Philips Healthcare  

Diagnostic Segment Revenue: $9.15B 

Founded Year: 1891 

Total Employees: 69062 

Headquarters:  Amsterdam, Netherlands 

Market Cap:  

Stock Exchange: AMS 

• Philips is a Dutch health technology company focused on the development and manufacturing of innovative products that promote health and well-being 

• The company operates across four key segments: Personal Health, Connected Care, Diagnosis & Treatment, and Others. The Diagnosis & Treatment segment includes Precision Diagnosis and Image-Guided Therapy solutions. In 2024, Philips reported a 5.96% decline in revenue compared to 2023, primarily due to lower sales across key markets 

• In November 2024, Philips expanded its strategic collaboration with Amazon Web Services (AWS) to deliver its integrated diagnostics portfolio via the cloud. This includes solutions for radiology, digital pathology, cardiology, and AI-powered advanced visualization, aiming to improve clinical workflows and enhance diagnostic accuracy 

6. Abbott Laboratories 

Diagnostic Segment Revenue: $9.34B 

Founded Year: 1888 

Total Employees: 114000 

Headquarters:  Illinois, United States 

Market Cap:  

Stock Exchange: NYSE 

• Abbott discovers, develops, and manufactures various healthcare products. The company develops diabetes care products, neuromodulation devices, and several other products for the treatment and diagnosis of cardiovascular diseases   

• The company operates in four business segments viz. pharmaceutical products, diagnostic products, nutritional products, and medical devices. Abbott provides different diagnostic solutions core laboratory, molecular, point of care & rapid diagnostics, and transfusion medicine. In 2024, the company’s revenue declined by 6.41% as compared to 2023, majorly driven by lower sales in rapid diagnostics  

• In October 2024, the WHO approved Abbott Molecular Inc.’s Alinity m MPXV assay as a first mpox in vitro diagnostic (IVD) under its Emergency Use Listing (EUL) procedure 

5. Quest Diagnostics 

Diagnostic Segment Revenue: $9.61B 

Founded Year: 1967 

Total Employees: 56000 

Headquarters:  New Jersey, United States 

Market Cap:  

Stock Exchange: NYSE 

• Quest Diagnostics is a leading American clinical laboratory company that collaborates with numerous hospitals and clinics worldwide. 

• The company operates through two main segments: Diagnostic Information Services (DIS) and Diagnostic Solutions. In 2024, Quest Diagnostics reported a 7.13% increase in revenue compared to 2023, primarily driven by growth in the DIS segment. 

• In September 2024, the company completed the acquisition of select laboratory assets from Allina Health, further strengthening its service capabilities 

4. Danaher 

Diagnostic Segment Revenue: $9.78B 

Founded Year: 1984 

Total Employees: 63000 

Headquarters:  Washington, DC 

Market Cap:  

Stock Exchange:  NYSE 

• Danaher is a diversified American conglomerate that designs, manufactures, and markets a broad range of medical, industrial, and commercial products and services 

• The company operates through three main segments: Biotechnology, Life Sciences, and Diagnostics. Its portfolio includes notable assets such as Aldevron and Abcam. In 2024, Danaher reported a 2.19% increase in revenue compared to 2023, driven by growth in core sales 

• In May 2024, Danaher announced a collaboration with Johns Hopkins University to develop innovative diagnostic methods for detecting mild traumatic brain injuries (TBI) 

3. Roche 

Diagnostic Segment Revenue: $15.85B 

Founded Year: 1896 

Total Employees: 103249 

Headquarters:  Basel, Switzerland 

Market Cap:  

Stock Exchange:  SWX 

• Roche is a global healthcare company engaged in the discovery, development, and commercialization of therapeutic and diagnostic products 

• The company operates through two main segments: Pharmaceuticals and Diagnostics. Its diagnostics division offers a comprehensive range of in vitro solutions, including molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point-of-care and patient self-testing, next-generation sequencing, lab automation and IT, and decision support tools. In 2024, Roche reported a 7.63% decline in revenue compared to 2023, primarily due to lower sales 

• In May 2024, the U.S. FDA approved Roche’s VENTANA MET (SP44) RxDx Assay as a companion diagnostic to identify non-squamous NSCLC patients eligible for Emrelis treatment 

2. GE Healthcare 

Diagnostic Segment Revenue: $16.49B 

Founded Year: 1994 

Total Employees: 53000 

Headquarters:  Chicago, Illinois 

Market Cap:  

Stock Exchange:  NASDAQ 

• GE HealthCare provides advanced MedTech solutions and services, including digital infrastructure, data analytics, and decision support tools 

• GE HealthCare operates through three main segments: Medical Imaging, Ultrasound, and Patient Monitoring Systems. In 2024, the company reported a 0.92% increase in revenue compared to 2023, primarily driven by improved pricing strategies 

• In December 2024, GE HealthCare launched Sonic DL for 3D, expanding its use of deep learning technology in MRI applications 

1. Siemens Healthineers 

Diagnostic Segment Revenue: $17.61B 

Founded Year: 1847 

Total Employees: 72000 

Headquarters:  Forchheim,Germany 

Market Cap:  

Stock Exchange:  ETR 

• Siemens Healthineers is a global German healthcare company specializing in medical imaging, diagnostics, cancer care, and minimally invasive therapies 

• Siemens operates under three business segments viz. Imaging, Diagnostics, Varian, and Advanced Therapies. The AVVIGO+ Guidance System and Getinge are among the various products of the company. In 2024, Siemens reported a 2.27% year-over-year revenue decline in USD, though it recorded growth in euros, reflecting currency exchange impact 

• In December 2024, the company expanded its Photon-Counting CT portfolio with the launch of the Naeotom Alpha class, featuring the Alpha.Peak, Alpha.Pro, and Alpha.Prime systems 

Criteria: We have taken public companies, and the companies are ranked based on their diagnostics segment revenue   

Sources:  

• Annual Reports   

• Quarterly Reports  

• Press Releases  

• Company Websites  

• Press releases  

• OANDA  

• Google Finance   

Related Post: Top 20 Diagnostic Companies of 2024